Research programme: angiogenesis inhibitors - AthenagenAlternative Names: ATG 001
Latest Information Update: 23 Aug 2006
At a glance
- Originator CoMentis
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Aug 2006 Discontinued - Preclinical for Cancer in USA (PO)
- 21 Sep 2005 Preclinical trials in Cancer in USA (PO)